Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.
Halabi
Susan
S
Small
Eric J
EJ
Vogelzang
Nicholas J
NJ
D015992:Body Mass Index; D002100:Cachexia; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D015999:Multivariate Analysis; D009765:Obesity / Q000150:complications; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology*; D016019:Survival Analysis